Vitiligo

Ted Lain, MD, shares his approach to evaluating patients with a vitiligo diagnosis and the search for concomitant disease.

A patient with vitiligo talks with Heather Woolery-Lloyd, MD, about her personal journey to diagnosis and struggles with the disease.

Expert dermatologists share final thoughts on treatment of vitiligo and topical ruxolitinib.

Experts in dermatology comment on the need to promote access to emerging treatments in vitiligo.

Heather Woolery-Lloyd, MD, and Nada Elbuluk, MD, share approaches to patient education and managing patient expectations when repigmenting the skin in vitiligo.

Expert dermatologists discuss the impact of vitiligo and vitiligo treatment on quality of life.

Nada Elbuluk, MD, and Ted Lain, MD, compare response to conventional treatment options vs emerging therapies, such as ruxolitinib, in the treatment of vitiligo.

Experts in dermatology share their impressions of ruxolitinib and approaches to vitiligo treatment in clinical practice.

Heather Woolery-Lloyd, MD, discusses the adverse event profile of topical ruxolitinib for treatment of vitiligo, highlighting the well-tolerated nature of the drug.

Expert dermatologists comment on the impact of UV light exposure on areas of the skin with vitiligo and their recommendations for sunscreen use.

Experts in dermatology review the mechanism of action and clinical trials of topical ruxolitinib for repigmenting the skin in vitiligo.

Brittany Craiglow, MD, discusses the lengthy nature of vitiligo treatment response and how to approach communicating with patients who want to see change quickly.

Ted Lain, MD, reviews the rates and patterns of repigmentation of the skin in vitiligo and how the timeline is different for each patient.

Expert dermatologists share approaches to treating patients with vitiligo, focusing on patient communication and the use of combination therapy.

Heather Woolery-Lloyd, MD, comments on the emotional impact of vitiligo on patients’ quality of life.

Ted Lain, MD, breaks down the use of the Vitiligo Area Scoring Index calculations to assess vitiligo severity.

Drs Brittany Craiglow and Nada Elbuluk review the precipitating factors that trigger vitiligo, as well as segmental vs nonsegmental vitiligo.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

New data from a study on adult vitiligo patients indicates that both autoimmune/autoinflammatory and non-autoimmune comorbidities have higher occurrence rates for vitiligo patients.

Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.

In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.

New research demonstrated that 5-fluorouracil and microneedling in conjunction showed stronger results for the 19 participants than tacrolimus monotherapy as a treatment for vitiligo.

New data suggests occupational exposure to certain melanocytotoxic chemicals may lead to vitiligo.

Dr. Raj Chovatiya shares his thoughts on the recent approval of ruxolitinib for treatment of vitiligo and where he might use it, either alone or in combination with other vitiligo treatments.

Iltefat Hamzavi, MD, explores key areas of patient communication that may shape adherence and outcomes in patients with vitiligo.

Seemal R. Desai, MD, examines the mechanisms of JAK inhibitors and why these agents play an important role in the treatment of vitiligo.

Pearl E. Grimes, MD, discusses intervention strategies for vitiligo, including stabilization, repigmentation, and maintenance. She also explores factors that impact therapeutic outcomes.